Amritsar Online

Glioblastoma Multiforme Market to Observe Impressive Growth by (2022-2032), Evaluates DelveInsight | Key Companies – Bayer, VBL Therapeutics, AstraZeneca, DNAtrix, Kintara Pharmaceuticals, Chimerix

 Breaking News
  • No posts were found

Glioblastoma Multiforme Market to Observe Impressive Growth by (2022-2032), Evaluates DelveInsight | Key Companies – Bayer, VBL Therapeutics, AstraZeneca, DNAtrix, Kintara Pharmaceuticals, Chimerix

September 20
22:21 2022
Glioblastoma Multiforme Market to Observe Impressive Growth by (2022-2032), Evaluates DelveInsight | Key Companies - Bayer, VBL Therapeutics, AstraZeneca, DNAtrix, Kintara Pharmaceuticals, Chimerix
DelveInsight’s “Glioblastoma Multiforme Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Glioblastoma Multiforme, historical and forecasted epidemiology as well as the Glioblastoma Multiforme market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Glioblastoma Multiforme market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Glioblastoma Multiforme pipeline products will significantly revolutionize the Glioblastoma Multiforme market dynamics.  

 

Glioblastoma Multiforme Overview

Glioblastoma Multiforme (GBM) is the most frequently occurring type of primary tumor of the central nervous system (CNS), mostly in adults, and its poor prognosis has not been significantly improved even though innovative diagnostic strategies and new therapies have been developed.

Glioblastoma Multiforme can be classified into primary and secondary Glioblastoma Multiforme. Primary Glioblastoma Multiforme occurs de novo without evidence of a less malignant precursor, while Secondary Glioblastoma Multiforme develops from initially low-grade diffuse astrocytoma (WHO grade II diffuse astrocytoma) or anaplastic astrocytoma (Grade III).

 

Some of the key facts of the Glioblastoma Multiforme Market Report: 

  • The Glioblastoma Multiforme market size is anticipated to grow with a significant CAGR during the study period (2019-2032) 
  • Kintara therapeutics announced data from two scientific posters for its Phase II clinical studies of VAL-083 for Glioblastoma Multiformetreatment. The data are being presented at the 26th Annual Scientific Meeting of the Society for Neuro-Oncology (SNO) being held in November 2021
  • In November 2021, Chimerix announced positive data in recurrent H3 K27M-mutant Diffuse Midline Glioma to be presented at the Society for Neuro-Oncology Annual Meeting
  • According to the study by Waschke et al., approximately 7,000 new cases of malignant brain tumors arise annually in Germany, with glioblastoma being the most common malignant brain tumor 
  • Key Glioblastoma Multiforme Companies: Bayer, VBL Therapeutics, AstraZeneca, DNAtrix, Kintara Pharmaceuticals, Chimerix, KaryoPharma, VBI Vaccines, Kazia Therapeutics, AivitaBiomedical, Medicenna Therapeutics, Immunomic Therapeutics, Treovir, Istari Oncology, Inovio Pharmaceuticals, Northwest Biotherapeutics, and others
  • Key Glioblastoma Multiforme Therapies: DNX-2401, ONC201, Selinexor (KPT-330), Paxalisib (GDC-0084), AV-GBM-1, MDNA55, VAL-083, and others
  • The Glioblastoma Multiforme epidemiology based on gender analyzed that Glioblastoma Multiforme is more prevalent among males than females

 

Get a Free sample for the Glioblastoma Multiforme Market Report 

 

Key benefits of the Glioblastoma Multiforme Market report:

  1. Glioblastoma Multiforme market report covers a descriptive overview and comprehensive insight of the Glioblastoma Multiforme Epidemiology and Glioblastoma Multiforme market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
  2. The Glioblastoma Multiforme market report provides insights on the current and emerging therapies.
  3. Glioblastoma Multiforme market report provides a global historical and forecasted market covering drug outreach in 7MM.
  4. The Glioblastoma Multiforme market report offers an edge that will help develop business strategies by understanding trends shaping and driving the Glioblastoma Multiforme market.

 

Discover more about therapies set to grab major Glioblastoma Multiforme market share @ Glioblastoma Multiforme market forecast

 

Glioblastoma Multiforme Epidemiology Segmentation:

The Glioblastoma Multiforme market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

  • Total Prevalence of Glioblastoma Multiforme
  • Prevalent Cases of Glioblastoma Multiforme by severity
  • Gender-specific Prevalence of Glioblastoma Multiforme
  • Diagnosed Cases of Episodic and Chronic Glioblastoma Multiforme 

 

Glioblastoma Multiforme Market  

The dynamics of the Glioblastoma Multiforme market are anticipated to change in the coming years owing to the expected launch of emerging therapies such as Selinexor(KPT-330), Paxalisib(GDC-0084), and others during the forecasted period 2019-2032. 

 

Download the report to understand which factors are driving Glioblastoma Multiforme epidemiology trends @ Glioblastoma Multiforme Epidemiological Insights 

 

Glioblastoma Multiforme Market Drivers

  • Robust Pipeline Activity
  • Glioblastoma Multiforme Therapies and Approval
  • Improved Treatment Deliverance
  • Emergence of Immunotherapies
  • Advancements in Genomics and Proteomics
  • Increasing Awareness Programs
  • Interventions that can cross the Blood-Brain-Barrier

 

Glioblastoma Multiforme Therapies and Key Companies

  • DNX-2401: DNAtrix
  • ONC201: Chimerix
  • Selinexor(KPT-330): Karyopharm Therapeutics
  • Paxalisib(GDC-0084): KaziaTherapeutics
  • AV-GBM-1: AivitaBiomedical
  • MDNA55: MedicennaTherapeutics
  • VAL-083: Kintara Therapeutics 

 

Scope of the Glioblastoma Multiforme Market Report

  • Study Period: 2019–2032
  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
  • Key Glioblastoma Multiforme Companies: Bayer, VBL Therapeutics, AstraZeneca, DNAtrix, Kintara Pharmaceuticals, Chimerix, KaryoPharma, VBI Vaccines, Kazia Therapeutics, AivitaBiomedical, Medicenna Therapeutics, Immunomic Therapeutics, Treovir, Istari Oncology, Inovio Pharmaceuticals, Northwest Biotherapeutics, and others
  • Key Glioblastoma Multiforme Therapies: DNX-2401, ONC201, Selinexor (KPT-330), Paxalisib (GDC-0084), AV-GBM-1, MDNA55, VAL-083, and others
  • Glioblastoma Multiforme Therapeutic Assessment: Glioblastoma Multiforme current marketed and Glioblastoma Multiforme emerging therapies
  • Glioblastoma Multiforme Market Dynamics:  Glioblastoma Multiforme market drivers and barriers 
  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
  • Unmet Needs, KOL’s views, Analyst’s views, Glioblastoma Multiforme  Market Access and Reimbursement 

 

Glioblastoma Multiforme Market Barriers

  • Multiple Treatment Challenges
  • High Treatment Cost
  • Fewer Patients Available for Clinical Trials
  • High Reccurrence Rate

 

Table of Contents 

1. Glioblastoma Multiforme Market Report Introduction

2. Executive Summary for Glioblastoma Multiforme

3. SWOT analysis of Glioblastoma Multiforme

4. Glioblastoma Multiforme Patient Share (%) Overview at a Glance

5. Glioblastoma Multiforme Market Overview at a Glance

6. Glioblastoma Multiforme Disease Background and Overview

7. Glioblastoma Multiforme Epidemiology and Patient Population

8. Country-Specific Patient Population of Glioblastoma Multiforme 

9. Glioblastoma Multiforme Current Treatment and Medical Practices

10. Glioblastoma Multiforme Unmet Needs

11. Glioblastoma Multiforme Emerging Therapies

12. Glioblastoma Multiforme Market Outlook

13. Country-Wise Glioblastoma Multiforme Market Analysis (2019–2032)

14. Glioblastoma Multiforme Market Access and Reimbursement of Therapies

15. Glioblastoma Multiforme Market drivers

16. Glioblastoma Multiforme Market barriers

17.  Glioblastoma Multiforme Appendix

18. Glioblastoma Multiforme Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

To know more about Glioblastoma Multiforme treatment, visit @ Glioblastoma Multiforme Medications

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Related Articles